Kami R. Whitney practices at Arjun Medical Center in Gainesville, Va. The author has disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2021 Dec 1;34(12):8-10. doi: 10.1097/01.JAA.0000795036.55877.c8.
Low-density lipoprotein-cholesterol (LDL-C) causes atherosclerosis and increases patient risk for cardiovascular mortality. However, patients who cannot tolerate statins present a treatment challenge. Bempedoic acid, an oral once-daily drug that reduces cholesterol synthesis, may help close this treatment gap. A meta-analysis demonstrated that bempedoic acid provides a well-tolerated and effective therapeutic option for lipid lowering in patients with hyperlipidemia, both as monotherapy and in combination with various other lipid-lowering agents. Also, although bempedoic acid acts on the same pathway as statins, it does not cause the muscular adverse reactions associated with statins.
低密度脂蛋白胆固醇（LDL-C）可导致动脉粥样硬化，并增加患者心血管死亡的风险。然而，不能耐受他汀类药物的患者存在治疗挑战。贝匹地酸是一种口服、每日一次的药物，可减少胆固醇合成，可能有助于缩小这一治疗差距。一项荟萃分析表明，贝匹地酸为高脂血症患者提供了一种耐受良好且有效的降脂治疗选择，无论是单药治疗还是与各种其他降脂药物联合使用。此外，尽管贝匹地酸作用于与他汀类药物相同的通路，但它不会引起与他汀类药物相关的肌肉不良反应。
